EGRAC and erythrocyte riboflavin measurements were conducted within 2 months of each another.
Riboflavin deficiency was defined as EGRAC [greater than or equal to] 1.
The log erythrocyte riboflavin concentration was negatively correlated with EGRAC (rz = 0.
The sensitivities (truepositive fractions) and specificities (true-negative fractions) of the test to determine deficiency based on EGRAC [greater than or equal to] 1.
For this reason, and as has been known for many years, EGRAC is sensitive in the short term to dietary intake of riboflavin (4).
It is accepted that there is a discrepancy between estimates of riboflavin deficiency through the use of EGRAC and estimates made from dietary intakes, such as to suggest either an overestimate of bioavailability or an inappropriately low EGRAC threshold for normality.
Plasma tHcy was significantly inversely correlated with plasma riboflavin and significantly positively associated with EGRAC (Table 3).
4 [micro]mol/L) higher in the highest EGRAC quartile compared with the lowest (P <0.
When plasma folate was included as a covariate in the analysis of EGRAC or plasma riboflavin and tHcy, the significance of the relationship was reduced (P = 0.
EGRAC was analyzed in triplicate, whereas riboflavin, FMN, and FAD were analyzed in duplicate.
EGRAC and plasma and erythrocyte concentrations of [B.
57), and both coenzyme forms were negatively associated with EGRAC (r = -0.